Skip to content

What is the optimal insulin amplitude for a square wave bolus in people with type 1 diabetes

What is the optimal amplitude for a square wave bolus of insulin aspart in children and young people aged 7-35years to control postprandial hyperglycaemia (postprandial blood glucose excursion at 1 hour <3mmol/L)?

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12612000609853
Enrollment
40
Registered
2012-06-07
Start date
2012-07-30
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

BACKGROUND: In patients with type 1 diabetes insulin is required to control the rise in blood sugar levels that occurs after eating. Insulin boluses may be given in 3 main ways - a standard bolus (rapid bolus of insulin usually given just prior to a meal), a square wave bolus (a fixed dose of insulin given over a set period of time) or a dual wave bolus (a combination of the previous 2 boluses). AIM: To determine the amplitude (dose) required for a square wave insulin bolus of two hours duration to maintain blood glucose levels (glycaemic control) when a standard carbohydrate (60g) meal is eaten. METHOD: 40 participants between the ages of 7 and 35 years with Type 1 Diabetes on insulin pump therapy will be recruited. The inclusion criteria are HbA1C </= 8%, Body Mass Index (BMI) <91st percentile, no complications of their diabetes and no other medical conditions. During a 1 week lead up to the study blood glucose control will be closely monitored. Participants will be contacted daily-2nd daily by a member of the research team. Adjustments may be made to the participant's insulin pump settings in conjunction with their treating endocrinologist. A continuous glucose monitoring system (CGMS) will be inserted on the first morning of the study. On this morning the participant will need to come to the hospital prior to breakfast. They will check their BGL 1 and 2 hours after insertion of CGMS for machine calibration. Participants will be provided with standard breakfast containing 60g of carbohydrate for each of the 6 days of the study. Insulin for the breakfast will be delivered as a square wave bolus over two hours starting just before the person starts eating. The bolus rate will be based on the participant's insulin: carbohydrate ratio and randomised each day to deliver a different percentage of this ratio (1:1 i.e 100% of the participant's insulin:carbohydrate dose for 2 hours, 1:2 i.e 50% of the participant's insulin:carbohydrate dose for 2 hours, 1:3, 1:4 and 1:6). The 6th bolus will be the participant’s standard bolus dose delivered as per usual practice. After the bolus is completed participants will return the pump to their usual basal rate. Participants should not eat until 4 hours after the test meal. Participants will self-monitor their blood glucose levels (BGLs) according to usual practice. If BGL is >18mmol/L at any time from >/= 4 hours after breakfast a correction bolus will be used. If the BGL goes below 3.5mmol/L or the participant has symptoms of hypoglycaemia at any time then they will eat 15 grams of carbohydrate. OUTCOMES: Primary outcome is the blood glucose excursion at 1 hour. Secondary outcomes include maximal blood glucose increase, maximal blood glucose excursion, time to maximal blood glucose excursion, time in target blood glucose range, area under the curve and hypoglycaemic events.

Interventions

Continuous subcutaneous insulin infusion with insulin aspart 6 different bolus doses based on participants' individual insulin:carbohydrate ratios. Dose 1: Standard bolus (rapid infusion) determined using participant's insulin:carbohydrate ratio Dose 2: Insulin dose determined using 100% of participant's individual insulin:carbohydrate ratio delivered over 2 hours Dose 3: Insulin dose determined using 50% of participant's individual insulin:carbohydrate ratio delivered over 2 hours Dose 4: Insu

Continuous subcutaneous insulin infusion with insulin aspart 6 different bolus doses based on participants' individual insulin:carbohydrate ratios. Dose 1: Standard bolus (rapid infusion) determined using participant's insulin:carbohydrate ratio Dose 2: Insulin dose determined using 100% of participant's individual insulin:carbohydrate ratio delivered over 2 hours Dose 3: Insulin dose determined using 50% of participant's individual insulin:carbohydrate ratio delivered over 2 hours Dose 4: Insulin dose determined using 33% of participant's individual insulin:carbohydrate ratio delivered over 2 hours Dose 5: Insulin dose determined using 25% of participant's individual insulin:carbohydrate ratio delivered over 2 hours Dose 6: Insulin dose determined using 17% of participant's individual insulin:carbohydrate ratio delivered over 2 hours After these doses participant's will return their insulin pump to their normal individually determined basal rate This is a crossover study where each participant will receive each of the doses on different days. The study will be run over 6 days with the participants being given each different dose with their breakfast meal. For the remainder of the day the participants will use their usual basal settings with their usual boluses for meals.

Sponsors

NovoNordisk Regional Support Scheme grant
Lead SponsorCommercial sector/Industry

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
7 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

Type 1 Diabetes Mellitus >/= 12 months Insulin pump therapy >/= 6 months Aged between 7 and 35 years HbA1c </= 8% (no lower limit)

Exclusion criteria

BMI >91st percentile Complications of their diabetes Major medical problems

Outcome results

None listed

Source: ANZCTR · Data processed: Mar 7, 2026